Rimactan 300 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

rimactan 300 mg

2care4 aps - rifampicin - kapsel, hard - 300 mg

Rimactan 300 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

rimactan 300 mg

orifarm as - rifampicin - kapsel, hard - 300 mg

Simbrinza ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

simbrinza

novartis europharm limited - brinzolamide, brimonidine tartrate - ocular hypertension; glaucoma, open-angle - Øyemidler - reduksjon av forhøyet intraokulært trykk (iop) hos voksne pasienter med åpenvinklet glaukom eller okulær hypertensjon for hvem monoterapi gir utilstrekkelig iop reduksjon.

Simbrinza 10 mg/ ml / 2 mg/ ml নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

simbrinza 10 mg/ ml / 2 mg/ ml

orifarm as - brinzolamid / brimonidintartrat - Øyedråper, suspensjon - 10 mg/ ml / 2 mg/ ml

Brinzolamid/Brimonidin Medical Valley 10 mg/ ml / 2 mg/ ml নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

brinzolamid/brimonidin medical valley 10 mg/ ml / 2 mg/ ml

medical valley invest ab - brinzolamid / brimonidintartrat - Øyedråper, suspensjon - 10 mg/ ml / 2 mg/ ml

Briviact 25 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

briviact 25 mg

2care4 aps - brivaracetam - tablett, filmdrasjert - 25 mg

Briviact 50 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

briviact 50 mg

2care4 aps - brivaracetam - tablett, filmdrasjert - 50 mg

Briviact 75 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

briviact 75 mg

2care4 aps - brivaracetam - tablett, filmdrasjert - 75 mg

Briviact 100 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

briviact 100 mg

2care4 aps - brivaracetam - tablett, filmdrasjert - 100 mg

Deltyba ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

deltyba

otsuka novel products gmbh - delamanid - tuberkulose, multidrug-resistent - antimykobakterielle - deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (mdr-tb) in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see sections 4. 2, 4. 4 og 5. det bør vurderes å offisielle retningslinjer for riktig bruk av antibakterielle midler.